Presentation is loading. Please wait.

Presentation is loading. Please wait.

The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural.

Published byDominic Golden Modified over 8 years ago

Similar presentations

Presentation on theme: "The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural."— Presentation transcript:

1 The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro George W. Cole, MD, Annette M. Alleva, MD, Rishindra M. Reddy, MD, Justin B. Maxhimer, BA, JingTong Zuo, MD, David S. Schrump, MD, Dao M. Nguyen, MD The Journal of Thoracic and Cardiovascular Surgery Volume 129, Issue 5, Pages 1010-1017 (May 2005) DOI: 10.1016/j.jtcvs.2004.10.040 Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions Terms and Conditions

2 Figure 1 The Journal of Thoracic and Cardiovascular Surgery 2005 129, 1010-1017DOI: (10.1016/j.jtcvs.2004.10.040) Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions Terms and Conditions

3 Figure 2 The Journal of Thoracic and Cardiovascular Surgery 2005 129, 1010-1017DOI: (10.1016/j.jtcvs.2004.10.040) Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions Terms and Conditions

4 Figure 3 The Journal of Thoracic and Cardiovascular Surgery 2005 129, 1010-1017DOI: (10.1016/j.jtcvs.2004.10.040) Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions Terms and Conditions

5 Figure 4 The Journal of Thoracic and Cardiovascular Surgery 2005 129, 1010-1017DOI: (10.1016/j.jtcvs.2004.10.040) Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions Terms and Conditions

6 Figure 5 The Journal of Thoracic and Cardiovascular Surgery 2005 129, 1010-1017DOI: (10.1016/j.jtcvs.2004.10.040) Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions Terms and Conditions

7 Figure 6 The Journal of Thoracic and Cardiovascular Surgery 2005 129, 1010-1017DOI: (10.1016/j.jtcvs.2004.10.040) Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions Terms and Conditions

8 Figure 7 The Journal of Thoracic and Cardiovascular Surgery 2005 129, 1010-1017DOI: (10.1016/j.jtcvs.2004.10.040) Copyright © 2005 The American Association for Thoracic Surgery Terms and Conditions Terms and Conditions

Download ppt "The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural."

Similar presentations

Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling.

Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling.
Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein.

Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein.
Max B. Mitchell, MD  The Journal of Thoracic and Cardiovascular Surgery 

Max B. Mitchell, MD  The Journal of Thoracic and Cardiovascular Surgery 
Lost in translation The Journal of Thoracic and Cardiovascular Surgery

Lost in translation The Journal of Thoracic and Cardiovascular Surgery
Manuel J. Antunes, MD, PhD, DSc 

Manuel J. Antunes, MD, PhD, DSc 
Stephen D. Cassivi, MD, MSc, FRCSC, FACS 

Stephen D. Cassivi, MD, MSc, FRCSC, FACS 
Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein.

Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein.
The days of future past  Neel K. Ranganath, MD, Aubrey C. Galloway, MD 

The days of future past  Neel K. Ranganath, MD, Aubrey C. Galloway, MD 
Circulating tumor DNA: Solid data from liquid biopsies

Circulating tumor DNA: Solid data from liquid biopsies
Intrinsic cardiac stem cells are essential for regeneration

Intrinsic cardiac stem cells are essential for regeneration
Abracadabra I, II…HeartMate 3?

Abracadabra I, II…HeartMate 3?
Form ever follows function

Form ever follows function
William M. DeCampli, MD, PhD 

William M. DeCampli, MD, PhD 
How should we treat air leaks?

How should we treat air leaks?
What is the best approach for surgery of malignant pleural mesothelioma? It is to put our efforts into obtaining trustworthy evidence for practice  Tom.

What is the best approach for surgery of malignant pleural mesothelioma? It is to put our efforts into obtaining trustworthy evidence for practice  Tom.
Surgeons, valve repair in severely unbalanced atrioventricular septal defect, and the emperor's new clothes  David M. Overman, MD  The Journal of Thoracic.

Surgeons, valve repair in severely unbalanced atrioventricular septal defect, and the emperor's new clothes  David M. Overman, MD  The Journal of Thoracic.
Bigger The Journal of Thoracic and Cardiovascular Surgery

Bigger The Journal of Thoracic and Cardiovascular Surgery
The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural.

The selective epidermal growth factor receptor tyrosine kinase inhibitor PD suppresses expression of prometastasis phenotypes in malignant pleural.
Commentary: Pursuit of the green jacket: Mastery of the long and short games  Daniel P. Raymond, MD  The Journal of Thoracic and Cardiovascular Surgery 

Commentary: Pursuit of the green jacket: Mastery of the long and short games  Daniel P. Raymond, MD  The Journal of Thoracic and Cardiovascular Surgery 
The lord of the rings  Antonio Miceli, MD, PhD 

The lord of the rings  Antonio Miceli, MD, PhD 

Similar presentations

Ads by Google